NASDAQ:NERV Minerva Neurosciences Q3 2026 Earnings Results & Report $2.46 -0.17 (-6.27%) As of 02:17 PM Eastern This is a fair market value price provided by Massive. Learn more. Minerva Neurosciences missed analyst earnings expectations in its Q3 2026 results, released November 6, 2026. The company reported EPS of -$1.60 versus the -$0.14 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 6, 2026TimeBefore Market OpensConference Call9:00 AM ET Minerva Neurosciences EPS ResultsActual EPS-$1.60Consensus EPS -$0.14Beat/MissMissed by -$1.46One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersMinerva Neurosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Minerva Neurosciences Q3 2026 Earnings FAQ Did Minerva Neurosciences beat earnings estimates for Q3 2026? Minerva Neurosciences (NASDAQ:NERV) reported earnings of -$1.60 per share for Q3 2026, missing the consensus estimate of -$0.14. The report was announced on Friday, November 6, 2026. Minerva Neurosciences Earnings HeadlinesMinerva Neurosciences Provides Third Quarter 2026 Financial Results and Business UpdatesNovember 6, 2026 | globenewswire.comMinerva Neurosciences, Inc (NERV) - What Are Investment Firms Thinking About This Stock?November 2, 2026 | americanbankingnews.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 10 at 1:00 AM | Behind the Markets (Ad)Minerva Neurosciences (NASDAQ:NERV) Rating Lowered to Sell at Wall Street ZenOctober 31, 2026 | americanbankingnews.comMinerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in LondonOctober 29, 2026 | globenewswire.comMinerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of SchizophreniaOctober 28, 2026 | globenewswire.comSee More Minerva Neurosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Minerva Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Minerva Neurosciences and other key companies, straight to your email. Email Address About Minerva NeurosciencesMinerva Neurosciences (NASDAQ:NERV). is a biopharmaceutical company focused on developing treatments for central nervous system disorders. The company’s research has centered on conditions with significant unmet medical needs, including schizophrenia, depression and other psychiatric or neurological diseases. Minerva’s lead product candidate has been roluperidone, an investigational therapy designed to address the negative symptoms of schizophrenia, such as social withdrawal, reduced motivation and diminished emotional expression. The company has also pursued additional CNS drug candidates, including programs targeting depression and neurodegenerative disorders, through internal development and collaborative arrangements. Founded in 2013 and headquartered in Waltham, Massachusetts, Minerva has conducted clinical development activities in the United States and internationally. Its operations and product development efforts have been focused on advancing potential therapies through clinical testing and regulatory review rather than on commercialized pharmaceutical products.View Minerva Neurosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
